Positive assessment of the potential of CRP apheresis by the G-BA 

20.04.2023

To clarify the efficiency of CRP apheresis therapy, Pentracor GmbH contacted the G-BA (Gemeinsamer Bundesausschuss, the highest decision-making body of joint self-government in the German health care system) in November 2022. A key task of the G-BA is to establish the entitlement to benefits, e.g. B. of clinics and patients, based on scientific knowledge. So far, a controlled clinical study and a registry study have provided clear indications of successful therapy. The G-BA has certified that CRP apheresis has sufficient potential for testing in accordance with Section 137e SGB V. The test is carried out by a randomized, controlled, clinical study (trial study) in patients with anterior wall infarction.